Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Acanthe Développement H1 net loss widens to EUR 2.4 million; revenue falls to EUR 1.7 million

Acanthe Développement H1 net loss widens to EUR 2.4 million; revenue falls to EUR 1.7 million

BitgetBitget2026/09/29 16:04
  • Acanthe Développement posted a first-half net loss attributable to shareholders of EUR 2.4 million, widening from EUR 0.4 million a year earlier.
  • Revenue fell 8% to EUR 1.7 million, including EUR 1.5 million of rental income and EUR 0.2 million of recharged tenant expenses.
  • Operating result widened to a EUR 2.9 million loss from a EUR 0.6 million loss, while net rental income slipped 17% to EUR 1 million.
  • Property portfolio value stood at EUR 105.6 million, while the fair value of investment property fell 2.7%.
  • Net revalued assets attributable to shareholders totaled EUR 103.21 million, or EUR 0.6242 per share; a EUR 0.01 dividend is due Sept. 30.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acanthe Développement SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609291200OMX_____CNEWS_FR_GNW1001275221_fr) on September 29, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials

Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.

智通财经•2026/10/10 06:21